Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial

Overview

Journal Anticancer Res

Specialty Oncology

Date 2018 Oct 3

PMID 30275228

Citations 8

Authors

Masayuki Shinkai

Motohiro Imano

Yasutaka Chiba

Yoko Hiraki

Hiroaki Kato

Mitsuru Iwama

Osamu Shiraishi

Atsushi Yasuda

Masahiro Tsubaki

Shozo Nishida

Yutaka Kimura

Takushi Yasuda

Affiliations

Soon will be listed here.

Abstract

Aim: To conduct a phase II study of single intraperitoneal (i.p.) administration of paclitaxel followed by paclitaxel, cisplatin, and S-1 (PCS) chemotherapy for patients with gastric cancer with peritoneal metastasis (PM).

Patients And Methods: Staging laparotomy was performed to confirm PM. Initially, patients received i.p. paclitaxel. Beginning 7 days later, PCS was given every 3 weeks followed by second-look laparoscopy. Primary and secondary endpoints were the overall survival (OS) rate, and response rate and patient safety, respectively.

Results: Seventeen patients were enrolled. The overall response rate was 70.5% (12/17). Grade 3/4 toxic effects included neutropenia and leukopenia. After chemotherapy, PM disappearance was confirmed in 11 patients. Gastrectomy was eventually performed in 11 patients. The 1-year OS rate was 82.4% and the median survival time was 23.9 months considering the overall cohort.

Conclusion: Combination chemotherapy with i.p. paclitaxel and PCS is well tolerated and effective in patients with gastric cancer with PM.

Citing Articles

Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease.

Li A, Sedighim S, Tajik F, Khan A, Radhakrishnan V, Dayyani F J Gastrointest Cancer. 2024; 55(2):534-548.

PMID: 38277055 PMC: 11186907. DOI: 10.1007/s12029-023-00994-5.

Gastric Cancer (GC) with Peritoneal Metastases (PMs): An Overview of Italian PSM Oncoteam Evidence and Study Purposes.

Sammartino P, De Manzoni G, Marano L, Marrelli D, Biacchi D, Sommariva A Cancers (Basel). 2023; 15(12).

PMID: 37370747 PMC: 10296634. DOI: 10.3390/cancers15123137.

SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation.

Bin Y, Lan D, Bao W, Yang H, Zhou S, Huang F Trials. 2022; 23(1):211.

PMID: 35279214 PMC: 8917651. DOI: 10.1186/s13063-022-06143-w.

Review of Regional Therapies for Gastric Cancer with Peritoneal Metastases.

Sun B, Lee B Cancers (Basel). 2022; 14(3).

PMID: 35158837 PMC: 8833629. DOI: 10.3390/cancers14030570.

Retrospective Cohort Study of Intraoperative Administration of Sustained-Release 5-Fluorouracil Implants in Advanced Gastric Cancer Patients.

Ge J, Liu T, Lei T, Li X, Song K, Azizi S Front Pharmacol. 2021; 12:659258.

PMID: 33927633 PMC: 8076801. DOI: 10.3389/fphar.2021.659258.